Edit |   |
---|---|
Antigenic Specificity | CD164, Human |
Clone | 67D2 |
Host Species | Mouse |
Reactive Species | human |
Isotype | IgG1κ |
Format | APC-Vio 770 conjugate |
Size | 30 tests in 60 µL |
Concentration | 1:50 |
Applications | Flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD164 Antibody, anti-human, APC-Vio® 770. Clone 67D2 recognizes the human CD164 antigen, a single-pass type I membrane protein, which is also known as sialomucin core protein 24, multi-glycosylated core protein 24 (MUC-24), or endolyn. CD164 is expressed by subpopulations of CD34+ cells. These include the majority of clonogenic myeloid and erythroid progenitors and the hierarchically more primitive precursors. Biochemical and functional characterization of CD164 indicate that this protein exists as a homodimeric molecule of approximately 160 kDa that participates in the adhesion of CD34+ cells to bone marrow stroma and functions as a signaling molecule, inhibiting the recruitment of primitive hematopoietic cells into cell cycle. CD164 may also play an important role in prostate cancer metastasis and the infiltration of bone marrow by cancer cells. |
Immunogen | n/a |
Other Names | MGC-24, MUC-24, Endolyn |
Gene, Accession # | Gene ID: 8763 |
Catalog # | 130-120-139 |
Price | $154 |
Order / More Info | CD164, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Forde, S. et al. (2007) Endolyn (CD164) modulates the CXCL12-mediated migration of umbilical cord blood CD133+ cells. Blood 109: 1825-1833. | Zannettino, A. C. et al. (1998) The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesis. Blood 92 (8): 2613-2628. | Huang, A. F. et al. (2013) CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1α/CXCR4 axis. Mol. Cancer 12 (1): 115-115. |